Login

Lyra Therapeutics, Inc. 8-K/A SEC Filings

Filed On Filing
07 Jun 2024 8-K/A: Costs Associated with Exit or Disposal Activities

As previously announced, on May 16, 2024, the Board of Directors (the “Board”) of the Company approved a reduction in the Company’s workforce by up to 87 employees, effective on or about May 21, 2024 with respect to approximately 80 empl...

10 Dec 2020 8-K/A: Departure/Election of Directors or Officers; Compensation

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support